If you also use an oral or inhaled steroid medication, do not stop using it suddenly. Talk to your healthcare provider about this. Nucala injection is not approved for use in: HES in a child younger than 12 Asthma in a child younger than 6 ...
NUCALA is an add-on, prescription maintenance treatment for patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems. Learn about taking NUCALA at home Info about NUCALA sent straight to my inbox? Sign me up. By completing this form, you cert...
Eosinophils are one of multiple cell types and mediators that are involved in inflammation, and inflammation is an important component in the pathogenesis of asthma, EGPA, and HES. The exact way mepolizumab works in asthma, EGPA, and HES has not been definitively established. Nucala belongs to ...
In September 2019, the U.S. FDA approved Nucala for use in children as young as 6 years of age who have severe eosinophilic asthma. FDA approval is based on an open-label clinical trial (NCT02377427) which was conducted in 36 children aged 6 to 11 years who have severe asthma. Based ...
Severe asthma is defined as disease that can only be controlled with high-dose inhaled corticosteroids plus a second maintenance medication and/or systemic corticosteroids, or that remains uncontrolled despite optimal therapy.2 Severe asthma is increasingly recognized as a heterogeneous condition, as ...
NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severeasthmaand with an eosinophilic phenotype [seeUse In Specific Populations,Clinical Studies]. Limitations Of Use NUCALA is not indicated for the relief of acute bronchospasm or ...
NUCALA is a prescription medicine for the treatment of people 12 years of age and older with hypereosinophilic syndrome (HES). When you have HES, your eosinophil [ee-uh-sin-uh-fil] levels are elevated. Elevated levels of eosinophils can lead to inflammation throughout your body. This inflamma...